19 November 2024

HeiQ plc

("HeiQ" or the "Company")

Admission Statement

The Board of HeiQ plc a leading company in materials innovation and hygiene technologies, today announce the admission of its Ordinary Shares to trading on Asset Match ahead of its first auction.

It is intended that the first auction in the Company's shares will be held in December 2024. Thereafter, auctions are expected to be held every month. More information, including exact auction dates and details on how to buy and sell, are available on the company profile page.

The Directors of the Company are:
Robert Van De Kerkhof (*Non-Executive Director & Chair*)
Carlo Centonze (*Co-Founder & Chief Executive Officer*)
Xaver Hangartner (*Chief Financial Officer*)
Benjamin Bergo (*Non-Executive Director*)
Karen Brade (*Non-Executive Director*)

Registered office:
5th Floor, 15 Whitehall, London SW1A 2DD.

Carlo Centonze, Co-Founder & Chief Executive Officer of HeiQ plc, commented:
"The Board are really pleased to be working with Asset Match to provide ongoing liquidity for our shareholders and a platform for trading shares. We believe that the trading platform offers all required capabilities to enable a simple continuation of trading of our shares."

1. Company Description
Founded in 2005, **HeiQ plc** is a Swiss-based international company that is a global leader in biotech ingredients and specialty chemicals for diverse applications such as textiles, flooring, building materials, glass, plastics, probiotic cleaning, cosmetics, and more. Working with more than 1000 partners in over 60 countries, our goal is to infuse ordinary products with extraordinary qualities, offering our co-creation partners sustainable and disruptive solutions across industries.

2. Strategy and Prospects
Our business model focuses on the commercialization of existing and as well as the incubation of new technologies, driving shareholder value through sales growth, entry into lucrative markets, and value creation by disruptive innovation. Our business model consists of three distinct platform technology ventures, being HeiQ AeoniQ™, HeiQ Xpectra™, and HeiQ GrapheneX™, and two growth-orientated commercialized business units financing our ventures, being HeiQ Life Sciences (probiotic industrial biotech) and HeiQ Advanced Materials (textile, flooring, industrial, antimicrobial specialty chemicals). We have a robust track record of innovation, with over 200 technologies developed in partnership with 300 major brands, including Hanes, Burberry, HUGO BOSS, Lycra, Zara, Itochu, Bosch Siemens, Ecolab, Woellner, Americhem, Lixil, and many more. Our global team comprises 200 professionals from 30 nationalities across five continents. We're committed to shaping a future where everyday products drive positive change, one innovation at a time.

3. Board of Directors
Brief biographies of the Directors of the Company are set out below.

Robert Van De Kerkhof – Non-Executive Director & Chair
Robert Van de Kerkhof brings over three decades of comprehensive experience in general management and sustainability leadership to his role as Chairman of HeiQ's Board of Directors. With a profound understanding of the textiles industry, particularly in cellulosic fiber technology, Robert is a visionary leader committed to driving sustainable transformation. Robert has demonstrated his dedication to advancing sustainable practices within the industry. His profound insights and strategic acumen have been instrumental in his role as Chief Sustainability Officer and Board Member of Lenzing AG, a position he held until December 31, 2023. Robert has held prominent positions, including President of the Austrian Fiber Institute, President and Board Member of CIRFS – the European Man-made Fibres Association, and Chairman of the ReHubs Business Council for Euratex. As Chairman of HeiQ's Board of Directors, Robert Van de Kerkhof is poised to guide the company toward a future where innovation and sustainability converge to create a positive impact on both the industry and the planet.

Carlo Centonze – Co-Founder & Chief Executive Officer
Carlo studied Environmental Sciences and Forest Engineering (MSc) at the Swiss Federal Institute of Technology, ETH Zurich. He earned his Executive MBA at the University of St.Gallen (HSG). After his service as an army pilot, he started his professional career as co-founder of the ETH spin-off, myclimate, a non-profit organization and prominent provider of carbon offsetting measures. Since 2004, Carlo has served HeiQ as co-founder and CEO, developing the firm from a two-employee company to an over 200-employee company. He also serves as chairman of ECSA Group, a 111-year-old Swiss chemical and energy distributor with an annual consolidated turnover of over US$350 million, and is a member of the executive board of Science Industries, the Swiss association of the pharmaceutical, biotech, and chemical industries.

Xaver Hangartner – Chief Financial Officer
Xaver started his career in finance in 2005 after obtaining a bachelor's degree in Business Administration from the University of St.Gallen (HSG). At the beginning of his professional career, he worked with EY Switzerland as an auditor for industrial clients and graduated as a Swiss Certified Public Accountant in 2009. He later worked in various finance positions and led the global finance and accounting team of a listed Korean specialty chemical producer before joining HeiQ in 2018 as Head of Controlling. He was appointed Group Chief Financial Officer in October 2019.

Benjamin Bergo – Non-Executive Director
Having joined the board on 30 June 2014, Ben brings a wealth of experience in high-growth technology operations and venture capital. He currently serves as President and CEO of Visus Therapeutics, Inc., an ophthalmic drug development company with offices in Seattle, WA, and Irvine, CA. He has previously served on the board of several high-growth companies, including as a non-executive director at Lumos Diagnostics Holdings Ltd (ASX:LDX), a leading full-service provider of point-of-care diagnostic solutions; as a non-executive director of Planet Innovation Holdings Limited, a healthtech innovation and commercialization company, and he led investments into life sciences transactions at a seed stage venture fund between 2007 and 2011. Prior to this, Ben held management roles at Vision BioSystems, until the sale of Vision Systems Limited to Danaher Corporation in 2006.

Karen Brade – Non-Executive Director
Karen has extensive experience of project finance, private equity and asset management. She started her career at Citibank working on multi-national project finance transactions. Karen worked at CDC (Commonwealth Development Corporation), the UK Government's development finance institution, where she held positions in equity and debt investing, portfolio management, fund raising and investor development. Karen has been an adviser to hedge funds, family offices and private equity houses. She

currently serves as chairman of Aberdeen Japan Investment Trust plc; chairman of Keystone Positive Change Investment Trust plc; non-executive director and chair of audit at Augmentum Fintech plc and is an external panel member of the Albion Capital VCT investment committee.

4. Share capital and significant shareholders

At 19 November 2024 the Company's issued share capital consisted of 168,537,907 Ordinary Shares with 0.05 pence par value, each share having equal voting rights.

The Company does not hold any Ordinary Shares in treasury and therefore the number of Ordinary Shares with voting rights is 168,537,907.

The Ordinary Shares are not admitted to trading on any exchange or trading platform other than Asset Match, having exited the Main Market of the London Stock Exchange ("LSE") effective 19 November 2024.

The Company has been notified that the following shareholder(s) are interested in 3% or more of the issued share capital of the company:

Name of shareholder	*Number of Ordinary Shares*	*Percentage holding*
Darren Morcombe	35,047,587	21.98%
Carlo Centonze	17,627,435	10.20%
Cortegrande AG*	13,995,030	8.30%
Murray Height	8,018,063	4.76%

* Company wholly owned by Carlo Centonze and of which he is the sole Director.

5. Financial statements

The Company's latest results for 18-month period ended 30 June 2024 can be accessed on the company profile page.

6. Legal and Arbitration Proceedings

During the 12 months preceding the date of this document, neither the Company nor any of its subsidiaries has been engaged in or is currently engaged in any litigation or arbitration proceedings which have or may have had in the recent past a significant effect on the financial position of the Company and so far as the directors are aware, there are no such proceedings pending or threatened by or against the Company or any of its subsidiaries.

7. Responsibility Statement

The Directors of HeiQ plc, as set about above, accept responsibility for the information contained within this document. To the best of the knowledge and belief of the directors (who have taken reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

REMINDER: It is intended that the first auction in the Company's shares will be held in **December 2024**. Thereafter, auctions will be held at regular intervals. More information, including exact auction dates and

-- ENDS --